We are live on ! Find out more
KAM

Krensavage Asset Management Portfolio holdings

AUM $256M
1-Year Est. Return 69.63%
This Fund
S&P 500
This Quarter Est. Return
+3.27%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$290M
AUM Growth
+$1.82M
Cap. Flow
+$9.02M
Cap. Flow %
3.11%
Top 10 Hldgs %
99.68%
Holding
13
New
3
Increased
3
Reduced
7
Closed
–

Top Buys

Rank Stock Value
1
KOD icon
Kodiak Sciences
KOD
+$17.6M
2
BIIB icon
Biogen
BIIB
+$1.8M
3
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$1.26M
4
CAH icon
Cardinal Health
CAH
+$707K
5
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$398K

Top Sells

Rank Stock Value
1
MCK icon
McKesson
MCK
+$8.77M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.39M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$994K
4
UTHR icon
United Therapeutics
UTHR
+$610K
5
EXEL icon
Exelixis
EXEL
+$522K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REGN icon
1
Regeneron Pharmaceuticals
REGN
$78.5B
$46.7M 16.1%
66,880
-2,200
-3% -$1.39M
ENTA icon
2
Enanta Pharmaceuticals
ENTA
$366M
$39.1M 13.46%
548,828
-15,274
-3% -$994K
MCK icon
3
McKesson
MCK
$100B
$38M 13.1%
124,165
-32,259
-21% -$8.77M
ALKS icon
4
Alkermes
ALKS
$8.22B
$37.5M 12.92%
1,424,204
-18,761
-1% -$465K
UTHR icon
5
United Therapeutics
UTHR
$25.8B
$36.2M 12.47%
201,612
-3,200
-2% -$610K
EXEL icon
6
Exelixis
EXEL
$13.3B
$34.7M 11.96%
1,530,406
-26,713
-2% -$522K
TARO
7
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$24.5M 8.44%
565,951
+26,984
+5% +$1.26M
BIIB icon
8
Biogen
BIIB
$30B
$23.5M 8.08%
111,353
+8,300
+8% +$1.8M
EGRX
9
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$5.68M 1.96%
114,787
+8,300
+8% +$398K
KOD icon
10
Kodiak Sciences
KOD
$2.6B
$3.48M 1.2%
+450,600
New +$17.6M
CAH icon
11
Cardinal Health
CAH
$53.9B
$748K 0.26%
+13,200
New +$707K
NXTC icon
12
NextCure
NXTC
$16.8M
$149K 0.05%
2,549
-37
-1% -$2.31K
ASMB icon
13
Assembly Biosciences
ASMB
$498M
$21K 0.01%
+842
New +$18.1K

Similar funds

CIA
Corigliano Investment Advisers Raleigh, North Carolina $256M AUM 54.89% 1-Year Est. Return
2
2Xideas Kusnacht, Switzerland $255M AUM 0.46% 1-Year Est. Return
CIM
Caldwell Investment Management Toronto, Ontario, Canada $255M AUM 36.87% 1-Year Est. Return
JFG
Juno Financial Group Richmond, Virginia $255M AUM
PIP
Palisades Investment Partners Santa Monica, California $255M AUM 50.52% 1-Year Est. Return
LRIC
Long Road Investment Counsel Kalamazoo, Michigan $255M AUM 12.85% 1-Year Est. Return
GAMC
Garner Asset Management Corp Plano, Texas $255M AUM 22.93% 1-Year Est. Return
TIA
Tiemann Investment Advisors Menlo Park, California $255M AUM 21.35% 1-Year Est. Return

Krensavage Asset Management's Q1 2022 Portfolio in Review

As of Q1 2022, Krensavage Asset Management held 13 positions worth $290M, up 0.63% from $288M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Krensavage Asset Management deployed $9.02M of net new capital in Q1 2022, opening 3 new positions and adding to 3 existing holdings. Its largest new stake was Kodiak Sciences: 450,600 shares worth $3.48M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was McKesson, an estimated $8.77M trimmed.

  • Krensavage Asset Management's largest Q1 2022 buy was Kodiak Sciences: 450,600 shares worth $3.48M.
  • Krensavage Asset Management added most to Biogen in Q1 2022, an estimated $1.8M increase.
  • Krensavage Asset Management's biggest Q1 2022 reduction was McKesson, cutting an estimated $8.77M.
  • Krensavage Asset Management's ten largest holdings make up 100% of its $290M portfolio in Q1 2022.
  • Krensavage Asset Management opened 3 new positions and closed 0 in Q1 2022.
  • Krensavage Asset Management's portfolio value rose 0.63% quarter-over-quarter to $290M.

Based on Krensavage Asset Management's 13F filing for Q1 2022, filed 17 May 2022.